CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 54 enrolled
Drug / intervention
cediranib maleate +1 moredrug
Likely dose
Not stated in record
Key inclusion· 6
  • ✓Histologically confirmed epithelial, sarcomatous, or biphasic malignant pleural mesothelioma
  • ✓Unresectable disease; residual disease after prior cytoreductive surgery allowed
  • ✓Measurable disease by CT scan or MRI
  • ✓Prior treatment with platinum-based chemotherapy required
Key exclusion· 7
  • ✕No history of long QT syndrome; QTc ≤470 msec
  • ✕No prior thymidine kinase inhibitor against VEGFR1 or VEGFR2
  • ✕No other prior immunotherapy or biologic therapy (except anti-VEGF monoclonal antibodies allowed)
  • ✕No more than 1 prior chemotherapy regimen

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00243074
NCT00243074Phase 2Completed
CompareCT.gov

A Phase II Trial of Novel Oral Anti-Angiogenic Agent AZD2171 (NSC-732208) in Malignant Pleural Mesothelioma

National Cancer Institute (NCI)·interventional·Posted Oct 21, 2005·Updated Jan 23, 2018

In Brief

A Phase 2 clinical trial evaluating cediranib maleate and laboratory biomarker analysis for Advanced Malignant Mesothelioma and 3 related conditions. Completed, enrolled 54 participants across 1 site.

Detailed Summary

This phase II trial is study how well AZD2171 works in treating patients with malignant pleural mesothelioma that cannot be removed by surgery. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 21, 2005
Enrollment StartNov 1, 2005
Primary CompletionApr 1, 2010
Study CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 20.7 years ago

Interventions

cediranib maleatedrug

Given orally

laboratory biomarker analysisother

Correlative studies